Yes, Merck just added last month recruiting centers in their MSS trial with Vicriviroc + Keytruda. I’m sure they have seen great data also, and know what is coming. Vicriviroc failed with HIV in both unmet need in phase 3 and naive population phase 2, both failed efficacy and with 15% discontinued due to adverse effects and 5% develop resistance to Vicriviroc during the trials... not a good choice for cancer either imo.


https://clinicaltrials.gov/ct2/show/NCT03631407